Regulatory Considerations and Strategies for the Use of Artificial Intelligence in US Advertising and Promotion

Description: This presentation will discuss regulatory considerations for the use of artificial intelligence in advertising and promotion of prescription drug products and biologics in the United States. Presenters will discuss the current landscape facing regulatory affairs teams including the use of generative AI in advertising, the rapid expansion of AI summaries across web and email platforms, and the FDA’s current thinking on the use of AI in advertising.

Panelists will provide real-world examples demonstrating various applications of AI in prescription drug and biologic advertising along with corresponding regulatory considerations. The panel will also explore current research highlighting the strengths and risks associated with the use of AI in life science advertising. The panel will conclude with a discussion of the applicability of current FDA guidances on the topic of AI and which guidances provide appropriate recommendations for AI applications.